Advertisement

Modeling Study of Scaled-up HPV Vaccination and Cervical Cancer Screening

Advertisement

In a modeling study reported in The Lancet Oncology, Simms et al detailed the preventive effects on cervical cancer that could be achieved by scaled-up human papillomavirus (HPV) vaccination and cervical screening efforts with the aim of disease elimination.

The major modeling projections are summarized or reproduced below:

With no further intervention, 44.4 million cervical cancer cases would be diagnosed globally over the period 2020–2069, with almost two-thirds of cases occurring in low–Human Development Index (HDI) or medium-HDI countries.

Rapid scale-up of vaccination to 80% to 100% coverage globally by 2020 with a broad-spectrum HPV vaccine could avert 6.7 to 7.7 million cases in this period—but more than half of these cases would be averted after 2060. Implementation of HPV-based screening twice per lifetime at age 35 years and 45 years in all low- or middle-income countries with 70% coverage globally would move the effects of prevention forward and avert a total of 12.5 to 13.4 million cases in the next 50 years.

Rapid scale-up of combined high-coverage screening and vaccination from 2020 onwards would result in the average annual cervical cancer incidence declining to < 6 new cases (< 4 new cases) per 100,000 women by 2045–2049 (2055–2059) for very high–HDI countries; 2055–2059 (2065–2069) for high-HDI countries; 2065–2069 (2070–2079) for medium-HDI countries; and 2085–2089 (2090–2100 or beyond) for low-HDI countries.

More gradual scale-up over the period 2020 to 2050 (eg, 20%–45% vaccination coverage and 25%–70% once-per-lifetime screening coverage by 2030, increasing to 40%–90% vaccination coverage and 90% once-per-lifetime screening coverage by 2050) would lead to end of the century incidence rates per 100,000 women of 0.8 cases in very high–HDI countries, 1.3 cases in high-HDI countries, 4.4 cases in medium-HDI countries, and 14 cases in low-HDI countries.

Study Implications

The investigators concluded, “More than 44 million women will be diagnosed with cervical cancer in the next 50 years if primary and secondary prevention programs are not implemented in [low- and middle-income countries]. If high coverage vaccination can be implemented quickly, a substantial effect on the burden of disease will be seen after three to four decades … widespread coverage of both HPV vaccination and cervical screening from 2020 onwards has the potential to avert up to 12.5–13.4 million cervical cancer cases by 2069, and could achieve average cervical cancer incidence of around four per 100,000 women per year or less, for all country HDI categories, by the end of the century.”  

Karen Canfell, DPhil, of the Cancer Research Division, Cancer Council New South Wales, Sydney, is the corresponding author for The Lancet Oncology article.

Disclosure: The study was funded by the National Health and Medical Research Council Australia. The study authors' full disclosures can be found at thelancet.com.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.


Advertisement

Advertisement



Advertisement